ARCHIVES

Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression

This article is from The Cancer Letter archive.

Vol. 35 No. 11 | November 30, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Relies on Importation, Fast Approval, and Early Reporting to Combat Drug Shortages

February 24, 2012

NCI Chips In $2 Million For AACR Meeting; Advisors, Senior Staff Not Consulted.

June 20, 2003

In the Cancer Centers: Rosen Moves To City Of Hope

November 1, 2013

Duke Deans Acknowledge Withholding Key Document From Outside Reviewers

January 14, 2011

M.D. Anderson Closes Trials following FDA Requests for Data

February 16, 1996

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

July 26, 2013